We assessed the prevalence of epilepsy in an elderly population in The Netherlands. The study was conducted from 1991 to 1993 as part of the Rotterdam Study, a population-based door-to-door study of all elder ly people living in Ommoord, a suburb of Rotterdam, and included 5,559 persons aged 55-95 years. All subjects were screened for epilepsy through direct questions re garding the existence of epilepsy and antiepileptic drug (AED) use, in addition to relevant questions from the World Health Organization (WHO) protocol for epidemi ologic studies of neurologic diseases. Further evaluation of screen positives was made by a panel of 1 study phy sician and 4 epileptologists, who also classified all con firmed cases of epilepsy according to the classifications of the International League Against Epilepsy (ILAE), The overall prevalence of active epilepsy in our study popu lation was 0.9% including special syndromes and 0.8% excluding special syndromes. The prevalence increased with age from 0.7% for those aged 55-64 years to 1.2% for those aged 85-94 years. The increase with age was de tected among men and women both. Our study confirms other findings showing that the prevalence of active epi lepsy increases with age in the elderly. The prevalence figures in our study were high as compared with those of other population-based studies. Epilepsy appears to be a major cause of morbidity in the elderly.
survey o f the total population aged ^5 5 years in the district o f Ommoord in R o tte rd a m th e Netherlands (6) . The baseline survey took place from June 1990 until June 1993. Informed consent and permission to obtain relevant information from treating physi cians were obtained from all participants. Through out the Rotterdam Study, subjects were surveyed in random clusters. Epilepsy screening was incorpo rated at the time of the 25th random survey in June 1991. The total eligible population consisted o f 7,129 persons. Because the number o f subjects aged 5*95 years was to small to determine an accurate prevalence figure, we excluded this age group from our analysis, Therefore our total eligible population consisted of,7,081 persons, 5,559 (79%) of whom participated in the epilepsy screening.
Screening for epilepsy
The standard Rotterdam Study protocol con sisted of a home interview followed by physical ex aminations in a research center. The screening for epilepsy was conducted during the home interview by a trained research assistant and consisted o f one 141 142
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question directly inquiring about epilepsy (Have you ever experienced epilepsy or had an epileptic fit?) and three questions regarding possible symp toms of epilepsy that were taken from the World Health Organization (W HO) research protocol for the screening of neurological disorders in develop ing countries (7) , as follows: Have you ever lost consciousness? Have you ever had episodes where you lost contact with your surroundings? and Have you ever had any shaking of your arms and legs which you could not control? In addition, all cur rent drug prescriptions were registered and classi fied according to the A natom ical Therapeutic Chemical (ATC) classification index (8) . We de fined as screen-positive for epilepsy all persons who (a) self reported epilepsy or fits, or (b) used antiep ileptic drugs (AEDs: ATC-code N03), or (c) an swered yes to at least two of the three W H O ques tions .
Diagnostic workup and classification of epilepsy
For persons who reported having had epilepsy or seizures during their life (n = 97), as well as for persons receiving AEDs without reporting epilepsy (n = 24), additional information was obtained from general p ractitio n e r' s and specialists' m edical records, including E E G and computed tomography (CT) scan reports. For 22 subjects, no further infor mation was available from medical records and they were contacted by telephone by a specially trained physician who took a detailed medical and seizure history. A similar procedure was used for subjects who gave positive responses to at least two of the W H O screening questions but who neither reported having epilepsy or receiving AEDs (n = 192). Per sons without a telephone, those who did not answer the telephone on several occasions, and those who were unable to give a reliable history by telephone were invited to an in-person interview, either in their home or at the research center. If the history suggested the possibility of epilepsy, the subject was reinterviewed by 1 of 4 epileptologists (Drs. D. J. Beintema, C. A. E. H. van Oorschot, A. van Wieringen, and J. M . de Wilde-Ockeloen), and ad ditional information was obtained from the general practitioner and other medical records.
A ll 313 screen-positive persons were subse quently reviewed by a panel consisting of the study physician and the 4 epileptologists. From all avail able information, the panel then decided whether a subject had epilepsy and, if so, classified the epi lepsy according to the classification of the Interna tional League Against Epilepsy (IL A E ) (9) . Single seizures, treated or not, were classified as " epi lepsy-special syndromes5' according to 1989 IL A E guidelines (9) . Active epilepsy was defined as hav ing had a seizure within 5 years o f prevalence date, regardless of treatment (10) .
Data analysis
Prevalence was calculated by gender and 10-year age groups. We calculated the prevalence of active epilepsy and of lifetime epilepsy, which includes both active epilepsy and epilepsy in remission. Prevalence of active epilepsy was calculated both including and excluding special syndromes. To compare our results with those of other published studies, we also calculated the age-specific preva lences of active epilepsy, defined as having had a seizure within 5 years of prevalence date or current use of A E D s. The proportion of each IL A E subtype of epilepsy was reported by gender. Table 1 shows the age and gender distribution of the study population and the number of screenpositive individuals. O f the total population of 5,559 persons screened, 313 persons (5.6%) were screen positive. No screen-positive men were in the high est age category. Overall, 97 (1.7%) persons re ported epilepsy, 24 (0.4%) received AEDs without Abbreviations as in Table 1 .° Defined as having answered positively to at least two of the three WHO screening questions on epilepsy. Acute symptomatic (7) Remote symptomatic (3) Cryptogenic (10) Total (20) Eclampsia, acute CVA, fever, influenza encephalitis, alcohol withdrawal (2), cerebral anoxia CVA >1 year before seizure, Parkinson's disease, subdural hematoma Abnormal EEG or CT scan; no known antecedent cause (5) ; no abnormality on EEG or CT scan; no known antecendent cause (5) CVA, cerebrovascular accident; CT, computed tomography.
RESULTS
reporting epilepsy, and 192 (3.5%) persons were screen positive because of positive answers to the WHO questions even though they did not report epilepsy or treatment with AEDs. Table 2 shows results after verification of all screen-positive subjects. We confirmed 85 cases of epilepsy, or 27% of all screen positives. For 27 per sons (28%) who reported epilepsy, the diagnosis could not be confirmed. Eleven cases showed clear evidence from neurologists' records for a nonepi leptic cause of symptoms; sleep apnea, transient ischemic attack (n = 2), depression, psychogenic attacks (n = 2), muscle headaches, narcolepsy, amaurosis fugax with migraine, nocturnal urinary incontinence, and syncope. For the remaining 16 persons, no information regarding possible epilepsy or other paroxysmal disorder could be detected. Nine of them were reinterviewed by 1 of the epileptologists, who made a specific nonepilepsy diagno sis. No further information could be obtained in 7 individuals. O f the 24 subjects who received A E D s without reporting epilepsy, we concluded that only 4 had epilepsy. The reasons for treatm ent with AEDs for conditions other than epilepsy were di verse; 3 persons were prescribed clonazepam for restless legs syndrome, 7 persons received carbamazepine (CBZ) for trigeminal or hypoglossal neu ralgia, 1 subject received C B Z for manic-depressive psychosis; 1 was prescribed valproate (VPA) prophylactically after herpes encephalitis w ithout clin ical or E E G evidence of epilepsy, 5 persons w ith mental disorders were long-term barbiturate users, 2 persons were prescribed C B Z for polyneuropa thy, and 1 subject could not be verified as an A E D user. Table 3 summarizes the types o f epilepsies for both active and lifetime epilepsy and for men and women. Localization-related epilepsy was the most common type in both men and women. The second most common type of active epilepsy in men was special syndrome, whereas in women it was both undetermined epilepsy and special syndrome. Gen eralized epilepsy was relatively uncommon in both sexes. Table 4 summarizes all special syndromes. O f the 20 cases detected, 7 were acute symptomatic sei zures, 3 of which were subsequently treated with AEDs [stroke, alcohol withdrawal (n = 2)]. Three patients with remote symptomatic epilepsy were detected, all of whom received AEDs. The remain ing 10 patients had no determinable antecedent cause, but 5 of them had abnormalities on E E G or CT scan; 1 of the 5 patients subsequently was started on A E D treatment. Four of the 5 remaining subjects with no abnormality on E E G or CT scan were treated with AEDs.
The prevalence figures of epilepsy are shown in Table 5 . We noted an overall lifetime prevalence of epilepsy in this 55-95-year-old population of 15.3 cases in 1,000 and an overall prevalence of active epilepsy of 9.2 cases in 1,000. The prevalence of active epilepsy increased with advancing age, but the prevalence of lifetime epilepsy leveled off or even decreased in the highest age groups. When we excluded special syndromes, the overall prevalence for active epilepsy was 7.7 cases per 1,000 persons. When we included subjects treated with AEDs in the definition of active epilepsy, regardless of whether they had had a seizure in the last 5 years, the prevalence figures increased slightly (Table 6 ). a Only an overall prevalence figure for active epilepsy was given; 5.3 in 1,000.
DISCUSSION
Our study has several possible limitations. First, despite our best efforts, we were unable to obtain 100% participation. Although our participation rate was high given the age distribution of our study population, the prevalence o f epilepsy may be dif ferent among nonparticipants as compared with participants. A second issue concerns the sensitiv ity of our screening questions. The screening instru-
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A. DE LA COURT ETAL ment we used contained direct questions regarding epilepsy and current drug use, in addition to ques tions that were adapted from the W H O protocol originally designed for neuroepidemiological stud ies in developing countries (7) . Other studies have also used this protocol to screen for epilepsy (4, (11) (12) (13) . Nonetheless, although high sensitivities have been reported, the instrument has never been vali dated properly (14) . We did not include a sample of screen negatives because the prevalence among screen negatives is likely to be much lower than that in the total study population, and to obtain a stable and precise estimate of the prevalence among screen negatives, a very large sample would have been required. Therefore, we may have missed some cases of epilepsy, especially persons with par tial seizures. Finally, Alzheimer' s disease is a rec ognized risk factor for late-onset epilepsy (15, 16) . Because of underreporting of seizures and symp toms in demented patients, we may have missed some patients with both dementia and epilepsy. These various considerations make it likely that our prevalence figures are slight underestimates.
Comparisons among studies must take into ac count variations in methods and definitions (2) . Ta ble 7 compares the results of our study with those of several other recent investigations which provided age-specific prevalences of epilepsy. We classified special syndromes as epilepsy according to the 1989 IL A E classification (9) . The rationale of including special syndrome is debatable, however. Most acute symptomatic seizures are clearly not epi lepsy, and some subjects who immediately receive treatment with AEDs after a first cryptogenic or remote symptomatic seizure may or may not de velop epilepsy subsequently. Furthermore, single seizures that occurred long ago are likely to be un derreported. To enhance comparability, we report rates for active and lifetime epilepsy that exclude the special syndromes.
Few investigators have reported age-specific prevalence figures for active epilepsy in the elderly, and those that did generally provided rates consid erably lower than those we report. Screening for epilepsy relies on a willingness to report epilepsy or seizures or related symptoms. In the Rotterdam Study, screening for epilepsy was conducted as part of a much larger investigation of other diseases rel evant to aging and the participation rate was high (6) . This study context may have contributed to our identifying a large number of patients. For lifetime prevalence, however, our estimates are relatively low, in particular as compared with estimates from register-based studies. Because remission rates are estimated to exceed 61% at 10 years after of epi lepsy onset (17) , population-based studies of the lifetime prevalence of epilepsy may well suffer from recall bias and underreporting, resulting in consid erable underestimation, especially in the elderly. Besides, what researchers truly wish to ascertain is the cumulative incidence. Because mortality is in creased among subjects with epilepsy, as compared to subjects without epilepsy, lifetime prevalence will always underestimate cumulative incidence.
The results of our study confirm earlier findings indicating that the prevalence of active epilepsy in creases with age in the elderly. The prevalence fig ures in our study were high as compared with those o f other population-based studied. Epilepsy ap pears to be a major cause of morbidity in the el derly .
